Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced changes to its Board, with Ms Jane Bell retiring as Chair and Mr Philip Facchina taking over. Ms Lyn Cobley will chair the Audit and Risk Committee. The changes aim to enhance the Board’s expertise and strategic direction. Mesoblast focuses on allogeneic cellular medicines for inflammatory diseases and has a strong global intellectual property portfolio. The company’s Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy. Mesoblast plans to develop additional cell therapies for various indications. The company’s manufacturing processes aim to provide readily available cellular medicines to patients worldwide.

Read more at GlobeNewswire: Mesoblast Announces Changes to Board of Directors’